relebactam
FDA Accepts Antibiotics NDA and sNDA for Priority Review
The FDA granted priority reviews for two of Merck's antibiotics.
FEBRUARY 5, 2019
IMI/REL Shows Promise Against Drug-Resistant Infections
Merck's investigational combination relebactam-imipenem may fill a critical void in therapies effective against ...
SEPTEMBER 11, 2018
Investigational Relebactam Plus Imipenem-Cilastatin Effective Against CRE
A new antimicrobial combination appears effective and safe against CRE.
APRIL 24, 2018
Load more